IBP Stock +106.23% Since Nov ’07 Pick IBP Stock +106.23% Since Nov ’07 Pick Unlock Top Buy Picks

Range Low Price High Price Comment
30 days $24.47 $29.93 Friday, 12th Apr 2024 ARWR stock ended at $24.70. This is 3.82% less than the trading day before Thursday, 11th Apr 2024. During the day the stock fluctuated 4.21% from a day low at $24.47 to a day high of $25.50.
90 days $24.47 $36.72
52 weeks $20.67 $42.48

Historical Arrowhead Research Corporation prices
JSON

CSV

Date Open High Low Close Volume
2024-04-12 $25.34 $25.50 $24.47 $24.70 827 362
2024-04-11 $25.74 $25.74 $25.28 $25.68 637 015
2024-04-10 $25.26 $25.48 $24.81 $25.39 875 710
2024-04-09 $25.85 $26.48 $25.63 $26.25 605 777
2024-04-08 $25.96 $26.33 $25.37 $25.70 842 064
2024-04-05 $25.77 $26.43 $25.28 $25.78 693 210
2024-04-04 $26.36 $26.98 $25.85 $26.11 743 145
2024-04-03 $26.00 $26.54 $25.71 $26.48 681 824
2024-04-02 $27.34 $27.42 $25.90 $26.19 1 211 718
2024-04-01 $28.25 $28.50 $27.61 $28.24 598 505
2024-03-28 $28.75 $29.07 $28.10 $28.60 551 391
2024-03-27 $28.21 $28.87 $27.86 $28.70 510 513
2024-03-26 $28.21 $28.45 $27.50 $27.84 674 437
2024-03-25 $27.31 $27.95 $27.31 $27.89 504 157
2024-03-22 $28.16 $28.36 $27.18 $27.21 651 753
2024-03-21 $28.97 $29.93 $28.12 $28.23 1 049 410
2024-03-20 $27.50 $28.36 $27.09 $28.16 895 797
2024-03-19 $28.06 $28.38 $27.54 $27.77 964 428
2024-03-18 $28.28 $28.36 $27.21 $28.14 1 273 612
2024-03-15 $27.16 $29.01 $27.00 $28.28 3 406 393
2024-03-14 $28.16 $28.26 $27.02 $27.42 1 579 877
2024-03-13 $28.51 $29.15 $28.19 $28.59 1 456 638
2024-03-12 $29.23 $29.43 $28.26 $28.55 1 418 962
2024-03-11 $33.01 $33.02 $29.26 $29.40 2 291 231
2024-03-08 $33.58 $35.47 $33.38 $33.45 963 031
Click to get the best stock tips daily for free!

About Arrowhead Research Corporation

Arrowhead Research Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in P... ARWR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT